专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20040235755A1 Use of amino acids amino acid alogues, sugar phosphates and sugar phosphate analogues for treatment of tumors, treatment of sepsis and immunosuppression 审中-公开
标题翻译：使用氨基酸氨基酸标记，糖磷酸盐和糖类磷酸盐类似物治疗肿瘤，治疗败血症和免疫抑制
公开(公告)号：US20040235755A1
公开(公告)日：2004-11-25
申请号：US10471705
申请日：2004-06-04
发明人： Erich Eigenbrodt , Sybille Mazurek , Helmut Grimm
IPC分类号： A61K031/7024 , A61K031/401 , A61K031/198
CPC分类号： A61K31/70 , A61K31/197 , A61K31/198 , A61K31/365 , A61K31/401 , A61K31/661 , A61K31/6615 , A61K31/7024
摘要： The invention relates to methods for the treatment of tumors and/or for immune suppression and/or sepsis by modulating the association of the glycolysis enzyme complex/M2-PK and/or by inhibition of transaminases and/or separation of the binding of the malate dehydrogenase to p36 comprising administering a pharmaceutical composition comprising a substance selected from the group consisting of amino acids, amino acid analogs, sugar phosphates, sugar phosphate analogs, and mixtures of said substances.
摘要翻译：本发明涉及通过调节糖酵解酶复合物/ M2-PK的缔合和/或通过抑制转氨酶和/或分离苹果酸的结合来治疗肿瘤和/或免疫抑制和/或败血症的方法脱氢酶至p36，其包括施用包含选自氨基酸，氨基酸类似物，糖磷酸盐，糖类磷酸酯类似物和所述物质的混合物的物质的药物组合物。

72. 发明申请

US20030109500A1 Compositions and methods for use in targeting vascular destruction 失效
标题翻译：用于靶向血管破坏的组合物和方法
公开(公告)号：US20030109500A1
公开(公告)日：2003-06-12
申请号：US10218833
申请日：2002-08-14
发明人： Ronald W. Pero , David Sherris , Kevin G. Pinney , Vani P. Mocharla , Zhi Chen
IPC分类号： A61K031/66 , A61K031/135 , A61K031/67
CPC分类号： A61K31/661 , A61K31/6615 , A61K31/664
摘要： Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.
摘要翻译：通过给予配制成具有底物特异性的微血管磷酸酶的磷酸盐前体药物形式的足够量的细胞毒性剂来治疗具有肿瘤或非恶性高血管形成的温血动物，使得微血管优先超过其他正常组织，因为较少的细胞毒性前体药物形式被转化为高度细胞毒性的去磷酸化形式。

73. 发明授权

US06538038B1 Compositions and methods for use in targeting vascular destruction 有权
公开(公告)号：US06538038B1
公开(公告)日：2003-03-25
申请号：US09505402
申请日：2000-02-16
申请人： Ronald W. Pero , David Sherris
发明人： Ronald W. Pero , David Sherris
IPC分类号： A61K3105
CPC分类号： A61K31/661 , A61K31/6615 , A61K31/664
摘要： Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

74. 发明申请

US20020142995A1 Ammonium salts of hemoglobin allosteric effectors, and uses thereof 审中-公开
标题翻译：血红蛋白变构效应物的铵盐及其用途
公开(公告)号：US20020142995A1
公开(公告)日：2002-10-03
申请号：US09920310
申请日：2001-08-01
发明人： Yves Claude Nicolau , Jaime E. Lazarte , Dennis R. Alford
IPC分类号： A61K031/663 , C07F009/02
CPC分类号： C07F9/117 , A61K31/132 , A61K31/661 , A61K31/6615 , A61K31/663 , C07F9/093 , A61K2300/00
摘要： The present invention comprises compounds, compositions thereof, and methods capable of delivering a broad range of anionic molecules to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering a ligand for the allosteric site of hemoglobin to the cytoplasm of the red blood cells.
摘要翻译：本发明包括化合物，其组合物和能够将广泛范围的阴离子分子递送至哺乳动物细胞的细胞质的方法。在某些实施方案中，本发明涉及通过将血红蛋白的变构位点的配体递送至红细胞的细胞质来提高哺乳动物红细胞传递氧的能力的化合物，其组合物和方法。

75. 发明授权

US06353026B1 Regulation of phospholipase D activity 有权
标题翻译：调节磷脂酶D活性
公开(公告)号：US06353026B1
公开(公告)日：2002-03-05
申请号：US09525157
申请日：2000-03-14
申请人： Charles N. Serhan
发明人： Charles N. Serhan
IPC分类号： A61K3120
CPC分类号： A61K31/661 , A61K31/00 , A61K31/035 , A61K31/20 , A61K31/216 , A61K31/232 , A61K31/6615
摘要： Novel inhibitors of polyisoprenyl phosphate signaling regulates phopholipase D activity.
摘要翻译：新型磷酸聚异戊二烯抑制剂调节磷脂酶D活性

76. 发明授权

US5760022A Pharmaceutical composition with improved bioavailability of inositol phosphate 失效
标题翻译：具有改善的磷酸肌醇生物利用度的药物组合物
公开(公告)号：US5760022A
公开(公告)日：1998-06-02
申请号：US676238
申请日：1996-07-17
申请人： Lars Persson , Torgny Gustafsson , Nicola Rehnberg
发明人： Lars Persson , Torgny Gustafsson , Nicola Rehnberg
IPC分类号： A61K9/107 , A61K31/075 , A61K31/20 , A61K31/66 , A61K47/10 , A61K47/14 , A61P3/00 , A61P43/00 , C07F9/655
CPC分类号： A61K31/6615 , A61K31/66 , Y10S514/946
摘要： The invention relates to an inositol phosphate containing pharmaceutical composition which comprises an aliphatic ester or ether for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one aliphatic ester or ether compound for the preparing of an inositol phosphate containing medicament with improved bioavailability of inositol phosphate in mammals including man at non-parenteral administration.
摘要翻译： PCT No.PCT / SE95 / 00064 Sec。 371日期：1996年7月17日 102（e）日期1996年7月17日PCT提交1995年1月24日PCT公布。公开号WO95 / 19775 日期：1995年7月27日本发明涉及含有肌醇磷酸酯的药物组合物，其包含脂肪族酯或醚，用于改善包括非肠胃外给药的人在内的哺乳动物中的磷酸肌醇的生物利用度。本发明还涉及使用至少一种脂肪族酯或醚化合物来制备含有肌醇磷酸酯的药物，所述药物具有改善的哺乳动物中肌醇磷酸酯的生物利用度，包括非肠胃外给药的人。

77. 发明授权

US5614511A Cosmetic compositions for treating itchy skin 失效
标题翻译：用于治疗瘙痒皮肤的化妆品组合物
公开(公告)号：US5614511A
公开(公告)日：1997-03-25
申请号：US616053
申请日：1996-03-11
申请人： Alexander P. Znaiden , Brian A. Crotty , Anthony W. Johnson
发明人： Alexander P. Znaiden , Brian A. Crotty , Anthony W. Johnson
IPC分类号： A61K8/55 , A61K8/92 , A61Q1/12 , A61Q7/00 , A61K31/66
CPC分类号： A61K31/6615 , A61K8/55 , A61K8/922 , A61Q1/12 , A61Q7/00
摘要： The invention is directed to controlling and alleviating itchiness of human skin. Itchiness is treated with a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.
摘要翻译：本发明涉及控制和减轻人皮肤的瘙痒。在化妆品上可接受的载体中，用含磷酸肌醇，特别是植酸及其盐的组合物处理瘙痒。

78. 发明授权

US5260288A Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives 失效
标题翻译：通过鞘氨醇-1-磷酸酯及其衍生物抑制细胞运动的方法
公开(公告)号：US5260288A
公开(公告)日：1993-11-09
申请号：US863179
申请日：1992-04-03
申请人： Yasuyuki Igarashi , Fugiang Ruan , Yoshito Sadahira , Shigeyuki Kawa , Sen-itiroh Hakomori
发明人： Yasuyuki Igarashi , Fugiang Ruan , Yoshito Sadahira , Shigeyuki Kawa , Sen-itiroh Hakomori
IPC分类号： A61K31/66 , A61P35/00 , C07F9/10 , C07F9/113 , C07F9/173
CPC分类号： A61K31/6615 , A61K31/66 , A61K31/661 , C07F9/113 , C07F9/173
摘要： A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of inhibiting inflammation due to motility and invasion into blood vessel walls of neutrophils comprising administering to a host in need of treatment an inflammation inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent. A method of preparing sphingosine-1-phosphate and its derivatives.
摘要翻译：一种抑制肿瘤细胞趋化性和/或化学侵袭运动性的方法，包括使肿瘤细胞与抑制量的选自鞘氨醇-1-磷酸的鞘氨醇-1-磷酸，鞘氨醇-1-磷酸的衍生物和鞘氨醇-1的模拟物磷酸盐或衍生物。一种抑制肿瘤细胞和嗜中性粒细胞的吞噬作用的方法包括使细胞与吞噬动力学抑制量的选自鞘氨醇-1-磷酸的鞘氨醇-1-磷酸，鞘氨醇-1-磷酸的衍生物和鞘氨醇-1的模拟物磷酸盐或衍生物。一种抑制肿瘤细胞转移的方法，包括向需要治疗的宿主施用转移抑制量的选自鞘氨醇-1-磷酸的鞘氨醇-1-磷酸，鞘氨醇-1-磷酸的衍生物和鞘氨醇-1的模拟物磷酸盐或其衍生物，以及药学上可接受的盐。抑制由于运动性而侵入嗜中性粒细胞的血管壁的炎症的方法，包括对需要治疗的宿主施用炎症抑制量的选自鞘氨醇-1-磷酸的鞘氨醇-1-磷酸，鞘氨醇-1-磷酸的衍生物，磷酸盐，以及鞘氨醇-1-磷酸酯或衍生物的模拟物，以及药剂的药学上可接受的盐。鞘氨醇-1-磷酸及其衍生物的制备方法。

79. 发明授权

US11980677B2 Wet wipes with a cellulosic substrate and gentle lotion 有权
公开(公告)号：US11980677B2
公开(公告)日：2024-05-14
申请号：US17743529
申请日：2022-05-13
申请人： The Procter & Gamble Company
发明人： Randall Glenn Marsh , Amber Grace Teufel
IPC分类号： A61K8/00 , A47K10/32 , A61G19/00 , A61K8/02 , A61K8/37 , A61K8/73 , A61K31/235 , A61K31/6615 , A61Q19/10 , D04H1/4258
CPC分类号： A61K8/0208 , A61K8/027 , A61K31/235 , A61K31/6615 , A47K2010/3266 , D04H1/4258
摘要： A wet wipe with a substrate having cellulosic fibers and a lotion is provided. The lotion may have between about 96.0% and about 99.5%, by weight of the lotion, of water. The lotion may have a preservative system having benzoic acid and/or a salt thereof, succinic acid and/or a salt thereof, and phytic acid and/or a salt thereof. The lotion may also have a pH buffering system and a pH of about 3.5 to about 5.

80. 发明公开

US20240139219A1 COMBINATION OF A SERCA2 INHIBITOR AND A STING ACTIVATOR FOR USE IN TREATING AND/OR PREVENTING CANCER 审中-公开
公开(公告)号：US20240139219A1
公开(公告)日：2024-05-02
申请号：US18546300
申请日：2022-02-15
申请人： Centre national de la recherche scientifique , Université de Montpellier
发明人： Nadine LAGUETTE , Isabelle Krystel VILA , Alizée Julie STEER
IPC分类号： A61K31/6615 , A61K31/343 , A61K31/352 , A61K31/407 , A61K31/5415 , A61P35/00
CPC分类号： A61K31/6615 , A61K31/343 , A61K31/352 , A61K31/407 , A61K31/5415 , A61P35/00
摘要： The invention relates to products comprising at least one inhibitor of SERCA2 (Sarco/Endoplasmic Reticulum Ca2+−AT-Pase 2) according to the invention, and at least one activator of STING, as combination products for a simultaneous, separate or sequential use in the treatment and/or prevention of a cancer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式